Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

Yeh, Tzu-Lin; Tsai, Ming-Chieh; Tsai, Wen-Hsuan; Tu, Yu‐Kang; Chien, Kuo–Liong

doi:10.1371/journal.pone.0278685

Cited by 12 publications

(13 citation statements)

References 62 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of GLP-1 receptor agonists (GLP-1RAs) on glycemic control varies depending on whether they are short-acting or long-acting preparations [ 190 , 191 ]. Short-acting GLP-1RAs primarily work by slowing down the emptying of the stomach, as well as increasing insulin secretion, leading to a reduction in post-meal glucose levels.…”

Section: Current Developments In Diabetic Vascular Angiopathy Treatmentsmentioning

confidence: 99%

“…On the other hand, long-term GLP-1RAs focus on lowering fasting blood glucose levels by stimulating insulin secretion and reducing glucagon [ 192 ]. These differences in pharmacodynamics, along with the varying half-lives, may contribute to the differences in effectiveness observed in clinical trials [ 191 , 193 ].…”

Section: Current Developments In Diabetic Vascular Angiopathy Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches

Yin,

Fu,

Luo

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

Diabetic macroangiopathy, a prevalent and severe complication of diabetes mellitus, significantly contributes to the increased morbidity and mortality rates among affected individuals. This complex disorder involves multifaceted molecular mechanisms that lead to the dysfunction and damage of large blood vessels, including atherosclerosis (AS) and peripheral arterial disease. Understanding the intricate pathways underlying the development and progression of diabetic macroangiopathy is crucial for the development of effective therapeutic interventions. This review aims to shed light on the molecular mechanism implicated in the pathogenesis of diabetic macroangiopathy. We delve into the intricate interplay of chronic inflammation, oxidative stress, endothelial dysfunction, and dysregulated angiogenesis, all of which contribute to the vascular complications observed in this disorder. By exploring the molecular mechanism involved in the disease we provide insight into potential therapeutic targets and strategies. Moreover, we discuss the current therapeutic approaches used for treating diabetic macroangiopathy, including glycemic control, lipid-lowering agents, and vascular interventions.

show abstract

Section: Current Developments In Diabetic Vascular Angiopathy Treatmentsmentioning

confidence: 99%

Section: Current Developments In Diabetic Vascular Angiopathy Treatmentsmentioning

confidence: 99%

A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches

Yin,

Fu,

Luo

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…Obesity and type 2 diabetes mellitus (T2D) are interconnected epidemics with a high prevalence and individual and combined negative impacts on health (CDC, 2020, Hales, 2020. Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) -based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP), have been shown to improve glycemic control in patients with T2D and reduce weight in patients with and without T2D (Davies, 2015, Davies, 2021, Garvey, 2023, Jastreboff, 2022, Wilding, 2023, Yeh, 2023. GLP-1 RA have also demonstrated cardiovascular benefit in patients with and without T2D (Lincoff, 2023, Ussher, 2023.…”

Section: Introductionmentioning

confidence: 99%

Monitoring Report: GLP-1 RA Prescribing Trends - June 2024 Data

Gratzl,

Rodriguez,

Cartwright

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity. For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications. Objective: To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and December 31, 2023. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription. Results: 1,063,200 patients were prescribed a GLP-1 RA between January 2018 and December 2023, with 4,213,888 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 86.6% and AOMs accounted for 13.4%. The most common first-time medication was semaglutide (n = 559,880). Among those with available data, 71.5% of first-time ADM prescriptions overall and 74.9% in September 2023 had a fill within 60 days. By comparison, 45.6% of first-time AOM prescriptions overall and 32.1% in September 2023 had a fill within 60 days.

show abstract

“…17,18 Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide (3 mg) or semaglutide (2.4 mg) induced significant weight reduction and improvement in glycaemic control in adults with or without diabetes. [19][20][21][22][23] GLP-1 receptor agonist treatment also resulted in reduced waist circumference along with improvements in systolic blood pressure (SBP), triglycerides and high-density lipoprotein cholesterol. 19,20 Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist approved for T2D and in development for obesity, promoted weight reduction among people with or without T2D.…”

Section: Introductionmentioning

confidence: 99%

“…Treatment with glucagon‐like peptide‐1 (GLP‐1) receptor agonists such as liraglutide (3 mg) or semaglutide (2.4 mg) induced significant weight reduction and improvement in glycaemic control in adults with or without diabetes 19–23 . GLP‐1 receptor agonist treatment also resulted in reduced waist circumference along with improvements in systolic blood pressure (SBP), triglycerides and high‐density lipoprotein cholesterol 19,20 .…”

Section: Introductionmentioning

confidence: 99%

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

Hankosky,

Wang,

Neff

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimWe assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2 diabetes (T2D) among participants in the SURMOUNT‐1 trial.Materials and MethodsIn this post hoc analysis of SURMOUNT‐1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10‐year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo. Mean changes in risk scores from baseline to weeks 24 and 72 were compared between tirzepatide and placebo groups. Subgroup analyses were conducted based on participants' glycaemic status and body mass index at baseline.ResultsMean baseline T2D predicted risk scores did not differ between tirzepatide and placebo groups (range: 22.9%‐24.3%). At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%). At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%. For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo. At week 72, participants with prediabetes (range: 16.0%‐20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%‐11.3%). Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo.ConclusionTirzepatide treatment significantly reduced the 10‐year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.

show abstract

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

Cited by 12 publications

References 62 publications

A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches

A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches

Monitoring Report: GLP-1 RA Prescribing Trends - June 2024 Data

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial

Contact Info

Product

Resources

About